BioInvent Interim Report 1 January – 31 March 2012

Published: May 02, 2012

LUND, Sweden--(BUSINESS WIRE)--Regulatory News:

BioInvent International AB (publ) (OMXS:BINV)

· Enrolment of patients in the phase II GLACIER study with BI-204 (acute coronary syndrome) was completed in March. The first results are expected to be published in the third quarter.

· Treatment of all patients in BioInvent’s phase II study with TB-402 (thrombosis) was completed in the quarter. First results are expected to be published later in Q2.

Back to news